- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.


Nu.Q® Discover: Nu.Q® H3.1: A Breakthrough Immunoassay for Reliable and Robust NETs Quantification.
- Share
- Tweet
- Share on Facebook
- Share


Nu.Q® H3.1 is an advanced chemiluminescent immunoassay engineered for accurate and standardized quantification of neutrophil extracellular traps (NETs) via H3.1-nucleosomes in plasma. Nu.Q® H3.1 delivers high specificity and reproducibility, making it ideal for studying NET-related pathologies such as sepsis, COVID-19, and autoimmune diseases.
Download our application notes to find out more about this assay.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields